Skip to content

Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)

First Use of Parental Support Technology(R) for Single Gene Analysis Plus Aneuploidy Screening in Preimplantation Genetic Diagnosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01023048
Acronym
IVF008
Enrollment
56
Registered
2009-12-02
Start date
2009-11-30
Completion date
2014-03-31
Last updated
2014-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)

Keywords

preimplantation diagnosis

Brief summary

Gene Security Network has developed a novel technology called Parental SupportTM (PS) which is used for Preimplantation Genetic Screening/Diagnosis (PGS/D) during in vitro fertilization (IVF). This technology allows IVF physicians to identify embryos, prior to transfer to the uterus, which have the best chance of developing into healthy children. The purpose of this study is to validate clinical use of PS to detect specific genetic mutation(s) known to cause severe inheritable diseases in embryos produced by at-risk couples. This may be done while simultaneously testing these embryos for aneuploidy. This study will allow for first of its kind commercial PGS/D testing to detect disease-associated genetic mutations together with aneuploidy screening.

Interventions

OTHERpreimplantation diagnosis

genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)

Sponsors

Natera, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* couple (mother and father)at risk to have a child with a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia) * Able to provide laboratory report from commercial CLIA certified laboratory confirming presence of disease associated mutation in mother and/or father * couple planning to go through IVF and desiring PGD for the specified mutation * Father (male) willing and able to provide sperm sample * Maternal (female's) age \<40 years (e.g., 39 or younger) * CVS/Amnio planned once the pregnancy occurs; willing/able to provide amnio/cvs sample for confirmatory testing or provide test results of confirmatory testing performed by an external CLIA certified laboratory. * FSH \<10 (FSH = Follicle Stimulating Hormone. FSH is an indicator of egg quality and rough predictor of egg stimulation success. FSH is routinely measured by the IVF center prior to beginning an IVF cycle.)

Exclusion criteria

* Couples without prior documentation of genetic mutation as specified above * Adult couples where the male partner is not willing, able, or available to provide a semen sample. * Maternal age \>=40 years * Couple unwilling to have amnio/cvs

Design outcomes

Primary

MeasureTime frame
Confirm diagnosis through prenatal diagnosis (CVS or amniocentesis)10-20 weeks post intervention

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026